Evidence map›Paper›PMID 32941594›Full record

ArticleEuropean heart journal. Cardiovascular pharmacotherapy2022

Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing.

Seif El Hadidi, Giuseppe Rosano, Juan Tamargo, Stefan Agewall, Heinz Drexel, Juan Carlos Kaski, Alexander Niessner, Basil S Lewis, Andrew J S Coats, Gianluigi Savarese

Open access · bronzeAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal. Cardiovascular pharmacotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 8 countries.

Seif El HadidiDepartment of Pharmacy Practice and Clinical Pharmacy, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, New Cairo, Egypt.ORCID 0000-0002-0534-3809
Giuseppe RosanoDepartment of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy.ORCID 0000-0002-6868-4248
Juan TamargoDepartment of Pharmacology, School of Medicine, Universidad Complutense, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERCV, Madrid, Spain.ORCID 0000-0002-7979-7758
Stefan AgewallDepartment of Cardiology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-6942-6312
Heinz DrexelDepartment of of Internal Medicine and Cardiology, VIVIT Institute, Landeskrankenhaus Feldkirch, Feldkirch, Austria.ORCID 0000-0001-8191-9761
Juan Carlos KaskiDepartment of Molecular and Clinical Sciences Research Institute, St George's, University of London, St Georges Hospital, Room 0.246D, Corridor 9, Ground Floor, Jenner Wing, London, UK.ORCID 0000-0001-8068-0189
Alexander NiessnerDivision of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Basil S LewisDepartment of Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center and the Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.ORCID 0000-0001-5604-6399
Andrew J S CoatsDepartment of Pharmacology, Centre of Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy.ORCID 0000-0002-2771-4260
Gianluigi SavareseDepartment of Medicine, Karolinska Institutet and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Future University in Egypt · EGHospital General Universitario Gregorio Marañón · ESIRCCS Ospedale San Raffaele · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITKarolinska University Hospital · SELandeskrankenhaus Feldkirch · ATMedical University of Vienna · ATOslo University Hospital · NOSt George's Hospital · GBTechnion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a chronic debilitating and potentially life-threatening condition. HF patients are usually at high risk of polypharmacy and consequently, potentially inappropriate prescribing leading to poor clinical outcomes. Based on the published literature, a comprehensive HF-specific prescribing review tool is compiled to avoid medications that may cause HF or harm HF patients and to optimize the prescribing practice of HF guideline-directed medical therapies. Recommendations are made in line with the last versions of European Society of Cardiology (ESC) guidelines, ESC position papers, scientific evidence, and experts' opinions.

Indexed as

CardiologyHeart FailureHumansInappropriate PrescribingPolypharmacyStroke VolumeComorbiditiesHeart failureInappropriate prescribingPharmacotherapyReduced ejection fractionTherapeutic conflicts

Identifiers

PMID32941594
PMCPMC13453067
OpenAlexW3087049390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.